Provider comparison
Licensed Telehealth Providers, Compared
What the three largest US platforms actually charge for a GLP-1, graded on the same four criteria — and what each of them will not tell you.
- 1 of 3Publish enough pricing to compute a true twelve-month cost
- 0 of 3LegitScript certifications we could independently verify
- 2×How far one platform’s real monthly minimum exceeds its advertised price
- 13Billing periods in one platform’s year, not twelve
Disclosure: We currently have no affiliate relationship with any provider on this page and earn nothing from it. If that changes, this notice will say so and every paid link will be marked. Our grading criteria are published below and applied identically either way — see our affiliate disclosure.
How we grade
Four criteria, applied to every provider in the same way. Three of them are matters of public record. The fourth — what you will actually pay over a year — turns out to be the one most platforms will not answer.
- LegitScript certification — the third-party healthcare merchant credential Google and the major ad platforms require before an online clinic can advertise. Verified at the registry, not taken from the provider’s own badge.
- Pharmacy transparency — whether the platform publicly names which pharmacy fills your prescription. Only an estimated 15–20% of US telehealth GLP-1 providers do.
- Branded vs. compounded — FDA-approved branded medication has been through the full approval process. Compounded versions have not, and the regulatory ground under compounded GLP-1s shifted substantially in 2025 and 2026.
- True all-in cost — the twelve-month total at a maintenance dose, including membership, not the advertised headline.
The comparison
| Hims & Hers | Ro | Noom | |
|---|---|---|---|
| LegitScript | Badge displayed; not verified | Badge displayed; not verified | Badge displayed; not verified |
| Medication | Branded, with compounded retained on a limited scale | Branded | Both, on separate plans |
| Names its pharmacy | Partial — in SEC filings, not consumer pages | No | No |
| What the headline price covers | Medication only | Membership only | Medication included on compounded plans |
| All-in monthly | $298–$448 (starting dose) | $373–$598 | $249 or $279 (sources conflict) |
| 12 months at maintenance | Not published | $4,476–$7,176 | Unresolved |
Pricing read from each provider’s own published pages on 25 August 2026. Where a total is computed, both inputs come from the provider’s own pages and the arithmetic is shown below. For what the same medication costs bought direct from the manufacturer, and for the trade-offs of a compounded version, see those pages.
What each platform charges, in detail
- Hims & Hers — the advertised price is half the cost. Prices lead with “from $149” for the Wegovy pill, “from $199” for the pen, “from $299” for Zepbound. Those are medication only. A Hims Weight Loss Membership is mandatory and billed separately at $39 for the first month, then $149 a month. The real minimum is therefore $298, not $149. No price is published for any dose above the starting dose, despite the site displaying the dose ladder — so the twelve-month maintenance cost cannot be calculated from public information. The membership half alone comes to $1,678 a year.
- Ro — the only one that publishes dose-tiered pricing. Membership runs $39 for the first month, then $74 a month on annual prepay, $89 on six months, $99 on three, or $149 month to month. Medication is billed separately and priced by dose: the Wegovy pen is $199 at 0.25–0.5 mg but $349 from 1 mg upward. At a 2.4 mg maintenance dose with annual prepay that is $888 membership plus $4,188 medication — $5,076 for the year. Month to month it is $5,976. Zepbound at maintenance runs $6,276 to $7,176.
- Noom — medication included, but the pages disagree with each other. Alone among the three, Noom’s compounded plans include the medication in the price rather than billing it separately, which makes the headline figure meaningful. Two problems. Its own pages quote both $249 and $279 a month for the same named program, on the same day, and one of those pages contradicts its own FAQ. And Noom’s “month” is a four-week block, not a calendar month — its own billing language is “$279/month, billed as $837 for 12-weeks.” A 52-week year therefore contains thirteen billing periods, not twelve, which puts the annual cost above what the monthly figure implies.
What to ask
Ask any provider for the total twelve-month cost at a maintenance dose. One of these three can answer it from published information. The other two cannot.
What we could not verify
Publishing the gaps is part of the method. Each of these is marked as unverified in the table above rather than estimated.
- LegitScript status, all three providers. All three display a LegitScript badge on their own sites, which is the provider’s claim rather than a verification. The registry’s own lookup is protected by a CAPTCHA, so we could not confirm current status. We do not print a certification we have not checked.
- Hims & Hers medication pricing above the starting dose. Not published anywhere we could find. Reaching a real figure appears to require completing the intake flow.
- Ro’s prepaid medication rates. Ro advertises savings of “up to 50% on eligible medications” for prepayment but does not publish the resulting prices. Our twelve-month figures use month-to-month medication rates and may therefore be too high for a prepaying patient.
- Which of Noom’s two prices is current. $249 and $279 both appear on Noom’s own pages for the same program. We are not averaging them.
- Noom’s pharmacy partners, and whether they are 503A or 503B. Noom’s own safety page says compounded semaglutide is available “only through designated partner pharmacies” and names none.
Sources and method
- Provider pricing. Read directly from each provider’s own published pages on 25 August 2026: Hims & Hers, Ro, Noom. No affiliate or third-party pricing pages were used as sources.
- Hims & Hers medication policy. Strategic shift announcement, 9 March 2026.
- Hims & Hers pharmacy partners. Named in the company’s SEC filings rather than on consumer pages. We have not yet confirmed the current list against the latest filing, so the table records this as partial.
- Method. Figures are the providers’ own published numbers. Where we compute a total, every input is published by that provider and the arithmetic is shown. Assumptions are stated: our twelve-month figures assume a maintenance dose for all twelve months, so a real first year — which includes cheaper titration months — would come in lower.
GLP-1 medications explained → Patches vs. prescription → How we source and verify →
Pricing verified 25 August 2026. We recheck provider pricing quarterly.